GHK-Cu: the copper peptide in serums, and why injecting it is different

GHK-Cu is two products sharing one name. On a serum label it is a cosmetic ingredient, copper tripeptide-1, with a small body of human skin studies behind it. In a vial it is an unapproved injectable drug with no human trials at all. GHK-Cu is not FDA-approved for any use, and it is listed with the other unapproved peptides in our Peptides A-Z. Almost every confusing thing you will read about it comes from blurring these two products together.

What is GHK-Cu?

GHK is a tripeptide, a chain of three amino acids: glycine, histidine and lysine. It binds copper very tightly, and the copper-bound form is GHK-Cu. It occurs naturally in human blood plasma and was first described in 1973. Reviews report plasma GHK levels of about 200 ng/mL at age 20 falling to about 80 ng/mL by age 60. The versions in skin care and in vials are made synthetically.

The same molecule appears under several names:

If you have wondered why copper peptide serums look blue, the color comes from the copper. The copper(II) complex absorbs visible light around 580 to 600 nm. A blue tint tells you copper is present. It tells you nothing about strength or purity.

What are the benefits of GHK-Cu?

The benefits are best established in lab work, and they get thinner as you move toward people. In skin cells and animal wounds, GHK-Cu increases collagen, elastin and glycosaminoglycan production and changes the activity of enzymes that break down skin proteins. A 2026 evidence-mapping review in Pharmaceutics, which searched through August 2026, called it “a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug.”

What the topical studies actually found

A 2026 systematic review in Aesthetic Surgery Journal found 20 eligible studies, of which 18 were preclinical and 2 were randomized controlled trials. A 2024 review called the absence of clinical studies “surprising” given how widely the ingredient is sold.

Three cautions apply to the whole body of work. The most cited cosmetic “trials” exist only as meeting abstracts. A 2026 systematic review found that about 35% of the primary GHK-Cu literature it covered was co-written by the researcher who first isolated the peptide and a colleague, both affiliated with a company that sells copper peptide products. And GHK-Cu does not pass easily through intact skin: in a 2015 laboratory study, no peptide crossed untreated human skin in nine hours, while skin pre-treated with microneedles let it through.

Topical GHK-Cu sits on the small-human-studies rung. A registered phase 2 trial (NCT07437586) is testing a gel on small standardized wounds in 60 healthy adults, and it was still recruiting with no results on November 2, 2026.

How long does it take to work? No study has answered that well. Human studies mostly ran 8 to 16 weeks, so a fair trial of any cosmetic serum is measured in months, and even then the evidence does not promise a visible change. Our topical GHK-Cu guide goes through each study and how to read a label, and our guide to copper peptide serums covers buying and using one. For hair, the closest human data a 2026 review could cite was a small case series that delivered copper peptides together with minoxidil and dutasteride, so the effect of GHK-Cu alone cannot be separated; see peptides for hair.

GHK-Cu side effects

Long use is not the same as measured safety. The topical ingredient has been sold in cosmetics for decades, according to the researchers who first studied it, but independent published safety data are scarce.

• On the skin. A 2024 review stated that no studies have been published on its side effects. A 2026 review flagged a hyperpigmentation (skin darkening) risk in one acne-scar study that paired GHK-Cu serum with microneedling. The 2026 eyebrow study reported no serious adverse effects in 18 people.
• Copper allergy. Copper is a recognized contact sensitizer in susceptible people, and a broken skin barrier or a penetration-enhancing product raises exposure.
• Injections. Unknown. See below.

A sting that does not settle, spreading redness or a rash is a reason to stop and show the label to a pharmacist or dermatologist. Trouble breathing or swelling of the face or throat after any product is an emergency. Cosmetic companies must report serious adverse events to FDA.

People with Wilson disease, an inherited condition in which copper cannot be cleared and builds up in the liver and brain, have a specific reason to ask their specialist before using any copper-containing product. No study has examined GHK-Cu in this group. We also found no data on pregnancy or breastfeeding.

Why injected GHK-Cu is a different question

None of the topical evidence carries over to injection. A cream sits on or in the upper skin, and an injection bypasses the barrier that keeps most of the peptide out. There is no published human trial of injected GHK-Cu, and a ClinicalTrials.gov search on November 2, 2026 found no registered one; the registered studies are of topical products or patches. The only injection data come from animals, such as a 1996 study that injected a tripeptide-copper complex into wounds on dogs’ paw pads.

What is unknown about injecting it:

• Immune reactions. FDA’s stated concern is that compounded injectable GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities.” Immunogenicity means the body mounting an immune response against the product.
• Human safety data. FDA’s same entry says “there are limited data in humans to inform safety-related considerations.”
• Copper load. The 2026 Pharmaceutics review calls cumulative copper burden the dominant long-term concern with repeated exposure, says labile (loosely held) copper can catalyze damaging reactions, and says dietary copper limits cannot be converted into limits for injection. Formal absorption, distribution and excretion studies of the intact complex have not been reported.
• Dose. No study has measured what blood levels an injection produces or how long they last. The GHK-Cu dosage page explains why there is no human dose.
• Product quality. Research-grade vials have no FDA-verified identity, purity, potency or sterility.

Where do you inject GHK-Cu? No injection site has been tested in a human trial, so there is no answer with evidence behind it. What about before-and-after photos? No controlled study of injected GHK-Cu exists, so those photos have no comparison group, no verified product and no record of what else changed, such as lighting, skin care or a procedure. Injectable blends that pair GHK-Cu with other unapproved peptides are covered on the glow blend page; combining unknowns does not reduce them.

Cosmetic or drug: why the same molecule has two legal lives

US law sorts products by intended use, not by ingredient. A cosmetic is something applied to the body “for cleansing, beautifying, promoting attractiveness, or altering the appearance.” A drug is something intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or function of the body. FDA says intended use is shown by the product’s claims, by why consumers choose it, and sometimes by its ingredients. Its own examples of claims that turn a product into a drug include claims to “regenerate cells” or “restore hair growth.”

So a copper peptide serum sold to improve the look of skin is a cosmetic and needs no FDA approval. Cosmetics are still regulated. Since the 2022 cosmetics law, companies must keep records supporting a product’s safety, report serious adverse events to FDA within 15 business days, and register manufacturing facilities, and FDA can order a recall in serious cases. The same molecule in a vial meant for injection is a drug, and because no GHK-Cu drug has ever been approved, it is an unapproved new drug. The legal status follows the product, not the peptide.

Is GHK-Cu legal? FDA status in detail

GHK-Cu has never had a New Drug Application. Its only drug-side regulatory history is in the 503A process, which decides which bulk substances state-licensed pharmacies may use to compound drugs for individual patients.

In practice, a pharmacy may compound a non-injectable GHK-Cu product, such as a cream, for a patient with a prescription under FDA’s interim category 1 policy, if the other 503A conditions are met. Injectable GHK-Cu sits in no category after the withdrawal, which restores nothing: it has no compounding route and remains an unapproved new drug. The October 2026 HHS enforcement policy that made headlines changes none of this, because GHK-Cu is not on its list and that policy covers single-ingredient products only. A future PCAC vote would be advice only, and as the BPC-157 history shows, a vote does not change the law until FDA publishes a rule.

What research use only actually means

Vials labeled “for research use only” are not legal to use on people. The phrase comes from 21 CFR 312.160, which lets a company ship an unapproved drug only for tests in laboratory animals or in test tubes, with a label reading “Not for use in humans.” FDA warning letters to peptide sellers, including one dated August 24, 2026, have found that “research use only” and “not for human or veterinary use” labels do not change the legal picture when the seller’s website shows the products are meant for people. The label is not a loophole.

Access, and what to ask first

Cosmetic serums are sold over the counter, and most do not state a percentage, which makes price a poor guide to strength. A compounded cream needs a prescription, and compounded drugs generally fall outside standard pharmacy benefits, so it would likely be paid for out of pocket. Injectable GHK-Cu has no approved product and no lawful source for injection.

If a dermatologist, med spa or clinic brings up GHK-Cu, it is reasonable to ask:

• Is this a cosmetic, a compounded prescription or an injection, and which route has human data?
• What percentage of copper tripeptide-1 is in it, and who tested that?
• If microneedling is involved, what goes into my skin, and is that product made for that use?
• Do I have a history of metal allergy, keloids or pigment problems that changes the risk?
• What result would you expect by 12 weeks, and how would we measure it?